Skip to main content

Growing Onglyza Cases May Prove to be a Burden for the Manufacturers

Growing Onglyza Cases May Prove to be a Burden for the Manufacturers

Growing Onglyza Cases May Prove to be a Burden for the Manufacturers

Introduction

A product liability lawsuit was filed in the U.S. District Court for the Southern District of Ohio by the widow of an Ohio man, who claims the use of Onglyza was the reason for the congestive heart failure suffered by her husband before his death.

Onglyza cases are centralized as a part of MDL No. 2809, which is witnessing a steady rise in the number of lawsuits as expected since its establishment in February, in the U.S. District Court for the Eastern District of Kentucky under U.S. District Judge Karen K. Caldwell.

Bristol-Myers Squibb and AstraZeneca are the defendants named in the Onglyza litigation over its alleged link to congestive heart failure and other side effects. Plaintiffs hold them responsible for not providing adequate cardiovascular injury warnings despite having the knowledge.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!